🔥 What’s Hot on CardioAdvocate
Timely updates. Clinical relevance. Clear next steps.
Medicine evolves. We highlight what actually changes how people should think, ask questions, or advocate for themselves.
We don’t chase attention. We track meaning.
📜 2026 ACC/AHA/NLA Dyslipidemia Guidelines: The Most Significant U.S. Lipid Update in Over a Decade
LANDMARK | JACC & Circulation | March 2026
What changed
The 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol, led by Roger Blumenthal and colleagues, represents a seismic shift in American lipid management. After 13 years of “percent reduction only,” absolute LDL-C and non-HDL-C treatment goals have returned — with tiered targets matching the intensity of a patient’s risk. The new PREVENT-ASCVD equations replace the Pooled Cohort Equations, with recalibrated thresholds (low <3%, borderline 3–<5%, intermediate 5–<10%, high ≥10%). Universal Lp(a) screening is now Class I for all adults. The Calculate-Personalize-Reclassify (CPR) framework replaces the old clinician-patient risk discussion with a structured, evidence-based algorithm. ApoB receives COR 2a. Coronary artery calcium gets a full 6-recommendation tiered system. Dietary supplements and CoQ10 both receive COR 3: No Benefit. New drug classes enter the algorithm: bempedoic acid, inclisiran, evinacumab, and olezarsen. And special populations — HIV, CKD, pregnancy, older adults — get dedicated, nuanced recommendations for the first time in a U.S. cholesterol guideline.
Why this matters
This guideline fundamentally changes the standard of care in the United States. Every CardioAdvocate article affected has been updated to reflect the new recommendations — 20 articles across the site. The return of absolute LDL-C goals means patients finally have a number to aim for, not a percentage to calculate. Universal Lp(a) screening means every adult should know their number. The CPR framework means risk assessment is no longer a one-time conversation but a layered, personalized process. And the courage to assign COR 3: No Benefit to supplements and CoQ10 — despite industry pressure — sends a clear message: evidence matters more than marketing. For our patients, this guideline also makes it significantly easier to get insurance authorization for therapies that were previously classified only as “may be considered” — now backed by hard guideline recommendations.
CardioAdvocate perspective
We applaud the direction and thank the writing committee for a comprehensive, forward-thinking document. But we remind our readers: much of what feels “new” in these guidelines is what preventive cardiologists and lipidologists have been practicing for years. We don’t wait for guidelines to catch up to the evidence — we use them for their intended purpose: to guide us, alongside position papers, expert consensus, and RCTs that haven’t yet made it into formal recommendations. We also continue to differ in certain areas — read our editorial for specifics.
Who should care
Every patient with elevated cholesterol, established ASCVD, or cardiovascular risk factors
Anyone taking (or considering) a statin, ezetimibe, PCSK9 inhibitor, or bempedoic acid
Patients who have never had their Lp(a) tested
Clinicians managing lipids in primary or secondary prevention
Go deeper →
Follow the Leader — Lipid Guidelines (Phenotype — Updated March 2026)
Little Napoleon Complex — Lipoprotein(a) (Phenotype — Updated)
A Picture Worth a Thousand Words — CAC (Phenotype — Updated)
There’s an App for That — Risk Calculators (Phenotype — Updated)
Hiding in Plain Sight — FH (Phenotype — Updated)
📝 CardioAdvocate Editorial: “A Step in the Right Direction”
NEW INSIGHT | CardioAdvocate Editorial | March 2026
What changed
CardioAdvocate has published a comprehensive editorial response to the 2026 ACC/AHA/NLA Dyslipidemia Guidelines. We break down what we applaud — including the return of absolute LDL-C goals, universal Lp(a) screening, the CPR personalization framework, and the courage to assign COR 3: No Benefit to supplements. We also detail where we continue to differ: CAC >300 should confer secondary prevention-equivalent risk (not waiting for >1000), ApoB deserves higher prominence given the growing problem of LDL-C discordance especially at lower levels, and inclisiran’s real-world LDL-C lowering may not match trial data. Most importantly, we discuss VESALIUS-CV — the evolocumab primary prevention trial showing 25% MACE reduction in high-risk patients without prior MI or stroke — and why clinicians don’t have to wait for the next guideline iteration to apply this evidence now.
Why this matters
Guidelines are guides, not guardrails. They represent the minimum standard of care, not the ceiling. This editorial reinforces CardioAdvocate’s core philosophy: personalize based on the best available evidence as it applies to the individual patient in front of you. Use guidelines, position papers, expert consensus, and landmark RCTs — don’t limit yourself to any single document. The CPR framework itself tells us to Calculate, Personalize, and Reclassify. We agree. And we’re grateful to the writing committee for the most important U.S. lipid document in over a decade.
Who should care
Patients who want to understand what the new guidelines mean for their care
Clinicians deciding how aggressively to treat based on CAC, ApoB, and Lp(a)
Anyone interested in how VESALIUS-CV changes the primary prevention conversation right now
Go deeper →
A Step in the Right Direction — 2026 Guidelines Editorial (Insight — NEW)
Follow the Leader — Lipid Guidelines (Phenotype — Updated)
📖 ESC Scientific Statement: Metabolic Risk Factors and the Heart
NEW | European Heart Journal | March 2026
What changed
The European Society of Cardiology just published a major scientific statement from five ESC working groups synthesizing the molecular and cellular mechanisms linking obesity, type 2 diabetes, and dyslipidemia to atherosclerosis, heart failure, ischemic heart disease, and arrhythmias. The statement introduces the cardiovascular-kidney-metabolic (CKM) syndrome staging framework (Stages 0–4), proposes a paradigm shift from treating CVD as a vascular problem to understanding it as a downstream consequence of systemic metabolic dysfunction, and draws a sharp mechanistic distinction between HFpEF (metabolic excess and nutrient toxicity) and HFrEF (metabolic insufficiency and energetic failure).
Why this matters
This statement validates the integrated cardiometabolic framework that CardioAdvocate has been building across our Phenotype articles. It reinforces that obesity, diabetes, dyslipidemia, and heart disease are not separate problems — they are interconnected metabolic drivers feeding the same vicious cycles. It also highlights how SGLT2 inhibitors and GLP-1 receptor agonists work through pleiotropic metabolic mechanisms far beyond glucose lowering — and why combining them may be synergistic. For patients, the takeaway is clear: metabolic health is cardiovascular health, and addressing the root metabolic dysfunction — not just individual risk factors in isolation — is the path forward.
Who should care
Patients managing multiple cardiometabolic conditions (obesity + diabetes + heart disease + CKD)
Anyone wondering why their cardiologist now talks about weight and metabolism
Clinicians seeking a unified mechanistic framework for the metabolic-cardiovascular connection
Go deeper →
See No Evil — Obesity (Phenotype — NEW)
The Enigma — HFpEF (Phenotype)
Drinking Buddies — AFib (Phenotype)
The Sweet Spot — Diabetes (Phenotype)
🙈 See No Evil: The Obesity Phenotype We Pretend Doesn’t Exist
NEW PHENOTYPE | CardioAdvocate Original | March 2026
What changed
CardioAdvocate’s newest Phenotype article tackles the condition that hides behind every other cardiovascular risk factor: obesity. Through the case of Marcus, a 52-year-old whose cardiologist never once discussed his weight, the article explores adiposopathy (“sick fat”), the insulin resistance cascade, and why BMI alone misses the most dangerous fat — visceral and epicardial adipose tissue. The Deep Dive covers the emerging cardiometabolic pharmacology landscape, including GLP-1 receptor agonists, dual agonists (tirzepatide), and the evidence that intentional weight loss reduces cardiovascular events independently of glucose control.
Why this matters
Obesity is the single most undertreated cardiovascular risk factor. Clinicians routinely address cholesterol, blood pressure, and diabetes — while avoiding the metabolic root cause. This article gives patients the language and framework to have that conversation. It also directly connects to the ESC metabolic statement and Packer’s adipokine hypothesis — building the scientific case that metabolic health is cardiovascular health.
Who should care
Anyone whose clinician treats their cholesterol and blood pressure but never discusses weight
Patients with metabolic syndrome, insulin resistance, or central obesity
Clinicians ready to address the elephant in the room
Go deeper →
See No Evil — Obesity (Phenotype — NEW)
The Sweet Spot — Diabetes (Phenotype)
The Enigma — HFpEF (Phenotype)
🐦 The Canary in the Coal Mine: Peripheral Artery Disease
NEW PHENOTYPE | CardioAdvocate Original | March 2026
What changed
PAD affects over 230 million people worldwide, yet fewer than 25% of patients are diagnosed before their first cardiovascular event. CardioAdvocate’s newest Phenotype article follows Robert, a 67-year-old whose leg pain was dismissed as “just getting older” — until a routine ABI test revealed severe peripheral artery disease. The article exposes why PAD remains the most underdiagnosed, undertreated, and underappreciated manifestation of systemic atherosclerosis — and why the referral gap between primary care and vascular specialists may be costing lives.
Why this matters
PAD is not just a leg problem — it is a whole-body warning signal. Patients with PAD have the same cardiovascular mortality risk as those with established coronary artery disease, yet they are far less likely to receive guideline-directed therapy including antiplatelet agents, statins, and structured exercise programs. The ankle-brachial index (ABI) is a simple, noninvasive, 5-minute screening test that remains dramatically underused in primary care.
Who should care
Anyone with leg pain, cramping, or fatigue when walking — especially smokers and diabetics
Patients over 65 who have never had an ABI screening
Clinicians who assume “no chest pain = no atherosclerosis”
Go deeper →
The Canary in the Coal Mine — PAD (Phenotype — NEW)
Cheating Death — Heart Attack Survivor (Phenotype)
There’s an App for That — Risk Calculators (Phenotype)
🎠 The Wild, Wild West: Supplements, Snake Oil, and Your Heart
NEW PHENOTYPE | CardioAdvocate Original | March 2026
What changed
Americans spend over $60 billion annually on dietary supplements — yet these products are regulated as foods, not drugs, under the 1994 DSHEA Act, with no requirement to prove safety or efficacy before reaching store shelves. CardioAdvocate’s newest Phenotype article follows Mrs. D., who walks into her cardiologist’s office with a bag of 14 supplements and asks, “Are these helping my heart?” The article exposes the regulatory void, the clinician’s dilemma when patients bring supplement lists, and the critical distinction between supplements and FDA-approved medications — a distinction most patients don’t know exists.
Why this matters
Many patients assume that if a supplement is sold at a pharmacy, it has been tested and approved. It hasn’t. The article walks through specific examples — nattokinase vs. actual anticoagulants, fish oil supplements vs. prescription icosapent ethyl, red yeast rice vs. statins — showing where the evidence supports, contradicts, or simply doesn’t exist for popular cardiovascular supplements. It also includes a firsthand account from a deployed military clinician who witnessed caffeinated MRE components causing cardiac emergencies in soldiers.
Who should care
Anyone taking supplements for heart health without discussing them with their clinician
Patients who assume “natural” means “safe” or “FDA-approved”
Clinicians overwhelmed by patients’ supplement lists
Go deeper →
The Wild, Wild West — Supplements (Phenotype — NEW)
Something Smells Fishy — EPA, DHA & Fish Oil (Phenotype)
🔍 Bias Is Everywhere: What Patients Don’t Know About How Decisions Get Made
NEW INSIGHT | CardioAdvocate Original | March 2026
What changed
Industry bias gets all the headlines — but it’s only one slice of a much bigger problem. CardioAdvocate’s newest Insight article examines five categories of bias that silently shape the care patients receive: government and system cost-driven bias (when treatment targets are set by budgets, not science), ethnic and cultural bias (when population-specific guidelines like the Indian Lipid Association targets aren’t applied), socioeconomic and affordability bias (when branded therapies aren’t discussed because of assumptions about a patient’s ability to pay), evidence hierarchy bias (when observational data and RCTs are treated as equivalent), and academic “no disclosures” bias (when the absence of industry ties creates its own blind spots).
Why this matters
Patients are rarely taught that the clinical recommendations they receive are filtered through multiple layers of bias — some visible, most not. This article gives patients specific questions to bring to their next appointment: “Might stricter guidelines be more appropriate for my ethnicity?” and “Are you not discussing a branded medication because of my perceived ability to pay — or because it costs your system too much?” A downloadable MyCardioAdvocate™ brief is now available.
Who should care
Every patient — bias affects all clinical encounters
Patients in large health systems (VA, Kaiser) where formulary constraints may limit options
Patients of South Asian, African, or other ethnic backgrounds where population-specific guidelines exist
Go deeper →
Bias Is Everywhere (Insight — NEW)
🔥 Breaking the Loop: The Cholesterol-Inflammation Fusion Hypothesis
NEW INSIGHT | JACC Asia | March 2026
What changed
Zeng and colleagues in JACC Asia articulate what many clinicians have long suspected: cholesterol and inflammation are not two separate problems — they are co-conspirators locked in a self-reinforcing cycle. Cholesterol crystals activate the NLRP3 inflammasome, releasing IL-1β; inflammation then suppresses cholesterol efflux transporters (ABCA1/ABCG1), trapping more cholesterol in the artery wall. Once established, this loop may be self-sustaining — even when LDL is “at goal.” CardioAdvocate’s newest Insight article explores this framework through the case of Linda, a 62-year-old who had a recurrent coronary event despite an LDL of 48 mg/dL.
Why this matters
This hypothesis reframes residual cardiovascular risk. It explains why REDUCE-IT may have worked through membrane-level disruption of cholesterol crystallization rather than triglyceride lowering, why JUPITER and REDUCE-IT may have enrolled the same fusion-prone phenotype, and why combination approaches — statins + colchicine + EPA — may be necessary to break the loop. It also raises provocative questions about whether CRP truly captures vascular inflammation or primarily reflects adiposopathy.
Who should care
Post-ACS patients with recurrent events despite “optimal” LDL
Patients with elevated triglycerides and/or hs-CRP on statin therapy
Clinicians still thinking “LDL at goal = job done”
Go deeper →
Breaking the Loop — The Fusion Hypothesis (Insight — NEW)
The Itch That Rashes — Inflammation (Phenotype)
Something Smells Fishy — EPA, DHA & Fish Oil (Phenotype)
🧬 Rewriting the Code: Gene Editing and the Future of Heart Disease
NEW INSIGHT | Gene Therapy | March 2026
What changed
From Jesse Gelsinger’s tragic death in 1999 to today’s CRISPR base editing targeting PCSK9, the gene therapy landscape has been completely transformed. CardioAdvocate’s newest Insight article traces this journey — including VERVE Therapeutics’ single-infusion PCSK9 base editing approach that permanently lowers LDL cholesterol by silencing a single gene in liver cells. The article explores four targets — PCSK9 silencing, ANGPTL3 knockout, Lp(a) reduction, and LDLR gene correction — and what each means for patients with familial hypercholesterolemia and treatment-resistant cardiovascular disease.
Why this matters
For the first time, we may be approaching an era where a single treatment — not a lifetime of pills or injections — could permanently correct the genetic drivers of atherosclerosis. But questions about safety, equity, access, and ethical governance remain unsettled. This article helps patients and families separate the science from the hype.
Who should care
Patients with familial hypercholesterolemia not at LDL goal despite maximal therapy
Anyone with elevated Lp(a) awaiting targeted therapies
Families affected by genetic cardiovascular disease
Go deeper →
Rewriting the Code — Gene Editing (Insight — NEW)
Hiding in Plain Sight — Familial Hypercholesterolemia (Phenotype)
Little Napoleon Complex — Lipoprotein(a) (Phenotype)
🧬 The Adipokine Hypothesis: A New Framework for HFpEF
COVER STORY | ACC Cardiology Magazine | March 2026
What changed
The March 2026 issue of ACC Cardiology Magazine features Dr. Milton Packer’s adipokine hypothesis as its cover story — a 105-page, 28,000-word paper with over 1,800 references that may fundamentally reshape how we understand HFpEF. The core argument: HFpEF is not primarily a cardiomyocyte disorder or a comorbidity-driven condition. It is a disease of dysfunctional visceral adipose tissue. Adipokines — signaling molecules from “sick fat” — drive sodium retention, inflammation, fibrosis, and cardiac remodeling. Epicardial adipose tissue is the unifying pathology. JACC Editor-in-Chief Dr. Harlan Krumholz calls the hypothesis “bold, densely argued and deliberately provocative.”
Why this matters
This hypothesis provides a coherent mechanistic rationale for why GLP-1 receptor agonists (semaglutide, tirzepatide) and SGLT2 inhibitors work in HFpEF — they shrink visceral fat and restore healthy adipokine biology. Separately, a JAMA Internal Medicine secondary analysis of the SOUL trial now shows oral semaglutide significantly reduces heart failure events in patients with type 2 diabetes and established HF — with benefit most pronounced in HFpEF.
Who should care
Anyone diagnosed with HFpEF, “diastolic dysfunction,” or told their EF is “normal”
Patients with metabolic syndrome, central obesity, and unexplained exercise intolerance
Clinicians managing HFpEF who want to understand why these therapies work
Go deeper →
“The Enigma” — HFpEF (Phenotype — Updated March 2026)
Packer: The Adipokine Hypothesis (JACC: Heart Failure)
⚠️ Young Adult Heart Attack Deaths Rising — Women Hit Hardest
ALERT | JAHA Study | February 27, 2026
What changed
A study of 945,977 hospitalizations published in the Journal of the American Heart Association (February 2026) reports that in-hospital STEMI deaths increased significantly among adults ages 18-54 between 2011 and 2022 — reversing years of declining MI mortality. Women experienced 3.1% in-hospital STEMI mortality compared to 2.6% for men. Despite similar complication rates, women received fewer cardiovascular procedures than men. Nontraditional risk factors — low income, kidney disease, and non-tobacco drug use — were more strongly linked to death than traditional risk factors like smoking and hypertension.
Why this matters
This reversal challenges the assumption that heart attacks are an “older person’s problem.” It confirms that primary prevention is failing young adults — especially young women — and that the implementation gap described in JACC Stats 2026 has real, measurable consequences. Young adults need aggressive risk assessment, and women need equal access to procedures when complications arise.
Who should care
Young adults (18-54), especially women
Anyone told they’re “too young to worry”
Clinicians relying on 10-year risk calculators for young patients
Go deeper →
Cheating Death — Heart Attack Survivor (Phenotype)
Wear Red for Women (Phenotype)
There’s an App for That — Risk Calculators (Phenotype)
🧬 Aortic Stenosis Genetics: GWAS Breakthroughs Point Toward Medical Prevention
NEW | Nature Genetics | February 26, 2026
What changed
Two landmark genome-wide association studies published in Nature Genetics have dramatically expanded our understanding of aortic stenosis genetics. Kany et al. used AI and deep learning on 59,571 UK Biobank MRI scans, identifying 166 genetic loci including PCSK9 and LDLR. Small et al. conducted a multi-ancestry GWAS of 86,864 aortic stenosis cases among 2.85 million individuals, identifying 241 autosomal risk loci and 54 new genes. The implicated loci are strikingly lipid-centric: LPA, PCSK9, LDLR, APOE. Mendelian randomization confirms that ApoB lipoproteins and Lp(a) are causally linked to aortic stenosis.
Why this matters
Previous statin trials (SALTIRE, SEAS, ASTRONOMER) failed to slow aortic stenosis progression — but they enrolled patients with established disease. These GWAS findings validate that the same lipoproteins causing atherosclerosis also initiate valve disease. Aortic stenosis is, in part, a lipid disorder — strengthening the case for early lipid-lowering, especially Lp(a) reduction, as primordial prevention of both coronary and valvular disease.
Who should care
Patients with elevated Lp(a) (at risk for valve disease, not just coronary disease)
Family members of people who’ve had valve replacement or TAVR
Anyone interested in the frontier of preventive cardiology
Go deeper →
The Ticking Time Bomb — Aortic Stenosis & Lp(a) (Phenotype — NEW)
Little Napoleon Complex — Lipoprotein(a) (Phenotype)
Follow the Leader — Lipid Guidelines (Phenotype)
🔴 AHA: 6 in 10 U.S. Women Will Have CVD by 2050
ALERT | AHA Scientific Statement | February 25, 2026
What changed
A major AHA Scientific Statement published in Circulation projects that nearly 6 in 10 U.S. women will have some form of cardiovascular disease by 2050. Hypertension among adult women is projected to rise from 48.6% to 59.1%, obesity from 43.9% to 61.2%, and diabetes from 14.9% to 25.3%. Among younger women (ages 22–44), close to 1 in 3 may have CVD by mid-century. Childhood obesity projections are staggering: nearly 1 in 3 girls ages 2–19, and 4 in 10 Black girls, are projected to have obesity by 2050.
Why this matters
Statement chair Dr. Karen Joynt Maddox stated: “We can’t treat our way out of this; we have to prevent our way out of this.” This is not a treatment crisis — it is a prevention crisis. Disease is beginning earlier, hitting harder, and disproportionately affecting women of color. Primordial prevention — addressing risk before it develops — must begin in childhood.
Who should care
Women of all ages, especially those in perimenopause and menopause
Parents of girls with early metabolic risk factors
Clinicians relying on short-term risk calculators that underestimate women’s lifetime burden
Go deeper →
Wear Red for Women (Phenotype)
There’s an App for That — Risk Calculators (Phenotype)
🫀 SGLT2 Inhibitors in Frailty — Evidence Says Yes, Hesitancy Persists
NEW | Treatment Paradox | February 23, 2026
What changed
Two publications this month highlight a treatment paradox: patients who may benefit most from SGLT2 inhibitors — frail older adults with heart failure — are least likely to receive them. The AGING-HF study (Circulation: Heart Failure) found that in 496 geriatric HF patients (mean age 90 years), SGLT2i use was associated with 33% lower all-cause mortality (HR 0.67). A Danish observational study found patients with moderate frailty were 14% less likely to be prescribed SGLT2i, and those with severe frailty 35% less likely — despite consistent benefits across frailty severities. The EMPA-ELDERLY trial confirmed empagliflozin improved glycemic control without compromising muscle mass or strength in older adults.
Why this matters
Therapeutic nihilism — the assumption that elderly or frail patients are “too old” or “too sick” to benefit from evidence-based therapy — is one of the most harmful forms of the implementation gap. The data say otherwise.
Who should care
Older adults with heart failure not currently on an SGLT2 inhibitor
Caregivers of frail patients with HF or diabetes
Clinicians hesitant to prescribe SGLT2i in elderly or frail populations
Go deeper →
“Too Little, Too Late?” — HFrEF (Phenotype)
The Older Adult (Phenotype)
💊 Oral PCSK9 Inhibitor Enlicitide — A Pill That Rivals Injections
NEW | Landmark Trial | February 2026
What changed
The CORALreef Lipids trial (NEJM, February 2026) demonstrated that enlicitide — a once-daily oral PCSK9 inhibitor — achieved 57% LDL-C reduction at 24 weeks in 2,909 patients, matching injectable PCSK9 inhibitors in a simple pill form. Over 70% of patients reached LDL-C <70 mg/dL with ≥50% reduction. Additionally, Lp(a) was reduced by 28%. Adverse events were comparable to placebo with 97% adherence.
Why this matters
Injectable PCSK9 inhibitors are dramatically underused despite proven efficacy — fewer than half of patients with established ASCVD currently reach LDL cholesterol goals. As lead investigator Ann Marie Navar (UT Southwestern) stated: an oral therapy this effective has the potential to dramatically improve cardiovascular prevention on a population level. The CORALreef Outcomes trial (completion 2029) will test whether this translates to reduced cardiovascular events.
Who should care
Patients not at LDL goal despite maximally tolerated statin therapy
Those who have declined or discontinued injectable PCSK9 inhibitors
Anyone with ASCVD or FH requiring aggressive lipid lowering
Clinicians seeking alternatives to injection burden
Go deeper →
Hiding in Plain Sight: Familial Hypercholesterolemia (Phenotype)
Follow the Leader — Lipid Guidelines (Phenotype)
💊 Combination Cardiometabolic Therapy — SGLT2i + GLP-1 RA Together
NEW | Meta-Analysis | February 2026
What changed
A new systematic review and meta-analysis in Diabetologia (2026) synthesizes data from 18 cohort studies with over one million participants, concluding that combining SGLT2 inhibitors with GLP-1 receptor agonists is associated with better cardiovascular, heart failure, and kidney outcomes than either therapy alone. This aligns with the 2026 ADA Standards of Care, which formally included GLP-1 RAs and dual GIP/GLP-1 RAs in the heart failure treatment algorithm for patients with symptomatic HFpEF and obesity. Prior JACC: Heart Failure data showed that adding a GLP-1 RA to SGLT2 inhibitors in HFpEF patients was associated with 32% lower risk of heart failure exacerbations.
Why this matters
The cardiometabolic treatment paradigm is shifting from single-agent approaches to synergistic combinations. Patients with overlapping diabetes, obesity, heart failure, and kidney disease may benefit from both agents working through complementary mechanisms. Yet many patients are still on only one — or neither.
Who should care
Patients with T2DM on only one cardiometabolic agent
Those with HFpEF and obesity not yet on both SGLT2i and GLP-1 RA
Clinicians managing cardiorenal-metabolic overlap
Go deeper →
The Sweet Spot — Diabetes (Phenotype)
The Enigma — HFpEF (Phenotype)
📊 JACC Stats 2026: U.S. Cardiovascular Health at a Crossroads
LANDMARK | Inaugural Report | February 2026
What changed
The inaugural JACC Cardiovascular Statistics 2026 report delivers a sobering reality check: despite extraordinary scientific advances and effective therapies, progress has stalled or reversed across key indicators over the past decade. Hypertension affects 1 in 2 U.S. adults with minimal change since 2009, and hypertension-related CV deaths have nearly doubled over two decades. Obesity now exceeds 40% of adults (up from 34.5% in 2011–2012). Most high-risk patients fail to reach LDL targets. Young adult AMI hospitalizations are rising after years of decline. As JACC Editor-in-Chief Harlan Krumholz stated: “If we want a healthier future, we must understand how far we have come, how far we have yet to go, and what stands in our way.”
Why this matters
This report quantifies the implementation gap that CardioAdvocate was built to address. We have the science. We have the therapies. What we lack is the bridge between evidence and everyday care. The data show that knowing what works is not enough — patients need to understand their own risk, ask the right questions, and advocate for treatments that are already proven. That is our mission.
Who should care
Every patient with hypertension, diabetes, obesity, or elevated cholesterol
Clinicians who assume their patients are at guideline-recommended targets
Policymakers and healthcare systems measuring quality of care
Anyone who believes “awareness” alone will close the gap
Go deeper →
Follow the Leader — Lipid Guidelines (Phenotype)
Under Pressure — Hypertension (Phenotype)
The Sweet Spot — Diabetes (Phenotype)
📊 CVD Risk Diverges by Age 35 — CARDIA Study Reveals Sex Gaps
NEW | Landmark Cohort Data | February 2026
What changed
A new analysis from the CARDIA study, published in JAHA, followed over 5,100 adults for more than 34 years. Men reached 5% CVD incidence 7 years earlier than women (age 50.5 vs 57.5). For coronary heart disease specifically, the gap was 10.1 years. Risk divergence begins at age 35 — not 40 as commonly assumed. Women are four times more likely to attend routine checkups (largely via gynecologic visits), representing a major missed opportunity for early cardiovascular screening in men.
Why this matters
These findings challenge conventional risk assessment timing and highlight that men are falling through the cracks during the critical decade between 35 and 45, when risk is accumulating but screening rarely happens. It also reinforces why sex-specific approaches to cardiovascular prevention are essential.
Who should care
Men aged 30–45 who haven’t had cardiovascular risk assessment
Women who assume their risk won’t begin until after menopause
Primary care clinicians setting screening timelines
Go deeper →
There’s an App for That — Risk Calculators (Phenotype)
Wear Red for Women (Phenotype)
💊 CTT Landmark: Most Listed Statin Side Effects Aren’t Real
Landmark Study | February 2026
What changed
The Cholesterol Treatment Trialists’ Collaboration published the largest meta-analysis of statin safety ever conducted — 19 double-blind RCTs, 123,940 participants. Of the 66 adverse effects listed on statin product labels, only 4 were actually caused by statins.
Why this matters
Statin hesitancy remains one of the most dangerous barriers to cardiovascular risk reduction. Many patients stop statins based on symptoms not actually caused by the medication.
Who should care
Anyone who has stopped or refused a statin due to feared side effects
Patients with statin intolerance labels
Clinicians navigating nocebo effects
Go deeper →
“Statins: Apocalypse or Pleiotropic Nirvana” (Phenotype)
🧬 2026 Is the Year of Lp(a) — From Research Curiosity to Treatment Target
Pipeline Watch | February 2026
What changed
Five drugs targeting lipoprotein(a) are advancing toward phase 3 readouts. Pelacarsen results are expected H1 2026, with regulatory filings to follow. OCEAN(a)-Outcomes for olpasiran completion December 2026. Muvalaplin, an oral small molecule achieving ~65% Lp(a) reduction, has a CVOT in progress. These trials will answer the critical question: does lowering Lp(a) reduce cardiovascular events?
Why this matters
If the answer is yes, Lp(a) testing may become essential for every patient with premature cardiovascular disease or a family history of heart attack or stroke. We may be witnessing the emergence of an entirely new treatment paradigm based on genetic risk rather than lifestyle modification alone.
Key trials to watch
Pelacarsen (Lp(a)HORIZON) — Novartis/Ionis ASO targeting Lp(a) mRNA
Olpasiran (OCEAN(a)-Outcomes) — Amgen siRNA targeting Lp(a)
Lepodisiran — Eli Lilly siRNA
Muvalaplin — Oral small molecule (~65% reduction)
Go deeper →
Little Napoleon Complex — Lipoprotein(a) (Phenotype)